MOG and experimental autoimmune encephalomyelitis: Autoimmune diseases have also been targeted, including autoimmune antibodies in myasthenia gravis, midkine in experimental autoimmune encephalomyelitis, IL-17A signalling factors in glucose-6-phosphate isomerase-induced rheumatoid arthritis and myelin oligodendrocyte glycoprotein -induced experimental autoimmune encephalomyelitis [44,45].